Neoadjuvant drug combo for stage 3 EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two drugs, sacituzumab tirumotecan and limertinib, given before surgery to people with stage 3 non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination can shrink the tumor enough to allow surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer with an EGFR mutation.
- Your cancer must be stage 3 (IIIA, IIIB, or IIIC) and not removable by immediate surgery.
- You must not have had any previous systemic cancer treatment.
- You must have good lung function and be able to tolerate surgery.
- You must be 18 years or older and have an ECOG performance status of 0 or 1.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs (sacituzumab tirumotecan plus a third-generation EGFR inhibitor) with or without radiation therapy for advanced lung cancer that has spread to the brain after prior EGFR inhibitor treatment. The goal is to see if this combination can better control the cancer and improve outcomes for patients with brain metastases.
This trial tests giving chemotherapy followed by the immunotherapy drug sintilimab before surgery for people with EGFR-mutant, early-stage non-small cell lung cancer. It aims to see if this combination reduces the tumor and improves outcomes before surgical removal.
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
This trial tests a combination of two drugs (sacituzumab tirumotecan and tagitanlimab) given before surgery for people with a specific type of lung cancer that is PD-L1 positive and can be removed. The goal is to see if this treatment helps shrink the tumor and improves outcomes after surgery.
This study tests a combination of two drugs for stage III lung cancer that can't be removed by surgery. One drug is an antibody-drug conjugate that targets cancer cells, and the other is an immunotherapy that helps your immune system fight cancer. The goal is to see if this combo shrinks or controls the tumor.
This trial tests a combination of two drugs — a targeted chemotherapy and an immunotherapy — given before surgery for people with early-stage but locally advanced lung cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
Hear when a new EGFR-mutant Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.